Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment

Bibliography

• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007;357:2153-65
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-18
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and other granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Resp Care Med 1999;160:736-55
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Thompson BW, et al. Two year prognosis of sarcoidosis. The ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003;20(3):204-11
   Google Scholar
• Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008;29:533-48
   PubMed Web of Science ®Google Scholar
• Grutters JC, van den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006;28:627-36
   PubMed Web of Science ®Google Scholar
• Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005(2):CD001114
   Google Scholar
• Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999;160:192-7
   PubMed Web of Science ®Google Scholar
• Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:60-6
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-81
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001;18:70-4
   Google Scholar
• Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842-7
   PubMed Web of Science ®Google Scholar
• Maini R, st Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932-9
   PubMed Web of Science ®Google Scholar
• Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802
   PubMed Web of Science ®Google Scholar
• Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis. Vasc Diffuse Lung Dis 2006;23:201-8
   PubMed Web of Science ®Google Scholar
• Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomized trial. Eur Respir J 2008;31:1189-96
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Studler U, Tamm M, Brutsche MH. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012;83:218-24
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Verzijlbergen JF, van Diepen DM, et al. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2008;25:143-9
   PubMed Web of Science ®Google Scholar
• Keijsers RG, Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Resp J 2013;41(3):743-51
   PubMed Web of Science ®Google Scholar
• Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Semin Respir Crit Care Med 2010;31(4):409-18
   PubMed Web of Science ®Google Scholar
• Grutters JC, Felllrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003;124(1):186-95
   PubMed Web of Science ®Google Scholar
• Kruit A, Grutters JC, Gerritsen WB, et al. ACE I/D–corrected Z-scores to identify normal and elevated ACE activity in sarcoidosis. Respir Med 2007;101:510-15
   PubMed Web of Science ®Google Scholar
• Vercoulen JHMM, Alberts M, Bleijenberg G. De checklist individual strength (CIS). Gedragstherapie 1999;32:131-6
   Google Scholar
• Ware J Jr, Sherbourne CD. The MOS 36 Item Short Form Health Survey (SF 36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83
   PubMed Web of Science ®Google Scholar
• McHorney A, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993;31:247-63
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Res J 2013; Epub ahead of print
   Google Scholar